| Autor: |
Huo RX; Department of Rheumatology and Immunology, Guangxi Academy of Medical Sciences, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, China. wcc2399571052@163.com., Yang YT, Yang Y, Huo XC, Meng DL, Huang RJ, Huang YJ, Lin JY, Zhu X, Wei CC, Huang XX |
| Jazyk: |
angličtina |
| Zdroj: |
European review for medical and pharmacological sciences [Eur Rev Med Pharmacol Sci] 2024 Mar; Vol. 28 (5), pp. 1864-1872. |
| DOI: |
10.26355/eurrev_202403_35600 |
| Abstrakt: |
Vasculitis is the inflammation of blood vessels caused by autoimmunity and/or autoinflammation, and its etiology and pathogenesis remain largely unknown. The Janus kinase (JAK) and Signal transduction Transcription Activator (STAT) signal transduction pathways are a group of molecules involved in the major pathways by which many cytokines exert and integrate their functions, and their dysregulation has been implicated in the pathogenesis of a variety of autoimmune diseases. However, current data supporting the role of the JAK/STAT pathway in the development of vasculitis is limited. In terms of treatment, glucocorticoids and immunosuppressants have been the standard therapy. However, because of the huge burden of treatment side effects, people have long waited for new treatment options. JAK inhibitors reduce the production of multiple cytokines and inhibit inflammation by targeting the JAK/STAT pathway, and have the advantage of rapidly acting in oral formulations, reducing glucocorticoid dependence and associated adverse events, especially in refractory cases. Therefore, JAK inhibitors are expected to be a promising drug for the treatment of vasculitis. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
